Comparative analysis of gene transcripts for cell signaling receptors in bone marrow-derived hematopoietic stem/progenitor cell and mesenchymal stromal cell populations

Khairul Anam and Thomas A Davis*

Abstract

Introduction: Knowing the repertoire of cell signaling receptors would provide pivotal insight into the developmental and regenerative capabilities of bone marrow cell (BMC)-derived hematopoietic stem/progenitor cells (HSPCs) and bone marrow mesenchymal stromal cells (BMMSCs).

Methods: Murine HSPCs were enriched from fluorescence-activated cell sorting (FACS)-sorted Lin<sup>−</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup> BMCs isolated from the tibia and femoral marrow compartments. Purified BMMSCs (CD73<sup>+</sup>, CD90<sup>+</sup>, CD105<sup>+</sup>, and CD45<sup>−</sup>, CD34<sup>−</sup>, CD31<sup>−</sup>, c-Kit<sup>−</sup>) with extensive self-renewal potential and multilineage differentiation capacity (into different mesodermal cell lineages including osteocytes, chondrocytes, adipocytes) were derived from adherent BMC cultures after CD45<sup>+</sup> cell depletion. Adherent colony-forming cells were passaged two to three times and FACS analysis was used to assess cell purity and validate cell-specific surface marker phenotype prior to experimentation. Gene transcripts for a number of cell signaling molecules were assessed using a custom quantitative real-time RT-PCR low-density microarray (94 genes; TaqMan® technology).

Results: We identified 16 mRNA transcripts that were specifically expressed in BMC-derived HSPC (including Ptprc, c-Kit, Csf3r, Csf2rb2, Ccr4, Cxcr3 and Tie-1), and 14 transcripts specifically expressed in BMMSCs (including Pdgfra, Ddr2, Ngfr, Mst1r, Fgfr2, Epha3, and Ephb3). We also identified 27 transcripts that were specifically upregulated (≥2-fold expression) in BMMSCs relative to HSPCs (Axl, Bmpr1a, Met, Pdgfrb, Fgfr1, Mertk, Cmkor1, Egfr, Epha7, and Ephb4), and 19 transcripts that were specifically upregulated in HSPCs relative to BMMSCs (Ccr1, Csf1r, Csf2ra, Epor, Il6ra, and Il7r). Eleven transcripts were equally expressed (<2-fold upregulation) in HSPCs and BMMSCs (Flt1, Insr, Kdr, Jak1, Agtrf1, Ccr3, Ednrb, Il3ra, Hoxb4, Tnfrsf1a, and Abcc1b), whilst another seven transcripts (Epha6, Epha8, Musk, Ntrk2, Ros1, Srms, and Tnk1) were not expressed in either cell population.

Conclusions: We demonstrate that besides their unique immunophenotype and functional differences, BMC-derived HSPCs and BMMSCs have different molecular receptor signaling transcript profiles linked to cell survival, growth, cell differentiation status, growth factor/cytokine production and genes involved in cell migration/trafficking/adhesion that may be critical to maintain their pluripotency, plasticity, and stem cell function.

* Correspondence: thomas.davis1@med.navy.mil

Regenerative Medicine Department, Operational and Undersea Medicine Directorate, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA

© 2013 Anam and Davis; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Adult stem cells are rare cell populations within specific tissues defined by their ability to undergo both self-renewal and differentiation. These tissue-specific stem cells are responsible for maintaining, generating, and replacing terminally differentiated cells of their host tissue as a consequence of physiologic cell turnover and or tissue damage due to injury [1,2]. Hematopoietic stem/progenitor cells (HSPCs) are functionally defined by their ability to self-renew and to contribute to all mature blood cell lineages [3]. Interestingly, HSPCs may contribute to non-hematopoietic tissues including the muscle, heart, brain and gut [4-7], which suggests an immense plasticity of differentiation and has raised the possibility of their use in tissue repair–regeneration [2]. Additionally, bone marrow and virtually all postnatal tissues contain small numbers of self-renewal multipotent adherent stromal–mesenchymal stem cells (MSCs) that have the potential to give rise to cells of diverse cell lineages, play a pivotal role in tissue repair–regeneration and have demonstrated nonimmunogenicity and potent immunomodulatory effects [8-10]. Furthermore, bone marrow-derived MSC (BMMSCs) have been shown to facilitate the in vivo engraftment of HSPCs and expansion of HSPCs in co-culture systems when used as feeder cells [11,12].

The self-renewal and differentiation of stem cells is probably subject to external modulation through receptors for a wide range of mediators including growth factors, cytokines, and chemokines. Furthermore, the potential diverse developmental plasticity of both HSPCs and BMMSCs to repair–replace damaged tissue suggests that local environmental factors and extrinsic influences drive stem cell differentiation and determine the function fate of these cells. Identification of the factors at the cellular and molecular levels that regulate the survival, proliferation, and development of these cells remains of key importance in identifying and propagating clinically relevant cell populations with diverse pathways of differentiation and therapeutic immunoregulatory potential.

Protein tyrosine kinase (PTK) networks are essential components of cell signaling pathways and play critical roles in cell proliferation, growth, development, metabolism and anti-apoptotic signaling, wherein they function to detect, amplify, filter and process environmental as well as intercellular signals [13]. PTKs include both transmembrane receptor tyrosine kinases (RTKs) and soluble cytoplasmic enzymes known as non-RTKs. In humans, 90 PTKs have been identified to date, comprising 58 RTKs and 32 non-RTKs [14]. Expression of most PTKs may be tightly regulated to retain unique features of a specific cell type. Characterizing the repertoire of high-affinity cell surface receptors for many growth factors, cytokines, chemokines and hormones might lead to a better understanding of the molecular phenotype and cell signaling pathways underlying the functional distinctions of bone marrow-derived HSPC and BMMSC populations.

The transcriptome of adult HSPCs and stromal stem/progenitor cells has been previously studied by other groups using high-density cDNA microarray hybridization techniques to comparatively decipher genes in undifferentiated cells and in developmentally regulated cell types involving various cellular processes including cell cycle, cell differentiation and cell proliferation [15-18]. Moreover, Son and colleagues investigated the expression profiles of PTK genes in undifferentiated and differentiated human embryonic stem cells [19]. High-density microarrays are an excellent tool for initial target discovery, but not the best tool for evaluating differential gene expression, whereas RT-PCR is often referred to as the gold standard for gene expression measurements [20,21]. In this study, we compared the gene expression profile of mRNA transcripts associated with signal transduction in bone marrow-derived undifferentiated highly purified Lin−ckit+Sca-1+ cells (LKSs) with BMMSCs using quantitative real-time RT-PCR (qRT-PCR), TaqMan® low-density array analysis (96 genes of interest including controls). Both sets of cells significantly differed in expression of key transcripts for RTKs, non-RTKs, cytokine-growth receptors, G-protein coupled receptors, and several other cell signaling molecules.

**Methods**

**Animals**

Five-week-old to six-week-old BALB/c mice were purchased from the National Cancer Institute (Fredrick, MD, USA) and housed in pathogen-free animal facilities at the Walter Reed Army Institute of Research (Silver Spring, MD, USA), which is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. All procedures were conducted using facilities and protocol approved by the Animal Care and Use Committee of Walter Reed Army Institute of Research (protocol #K07-05). Mice were housed five animals per cage prior to use. Mice were used for experimentation at 8 to 12 weeks of age. Animal rooms were maintained at 21 ± 2°C with 50 ± 10% humidity on a 12-hour light/dark cycle. Commercial rodent ration (Harlan Teklad Rodent Diet 8604) was available freely, as was acidified (pH 2.5) water to prevent opportunistic infections.

**Isolation of hematopoietic stem/progenitor cells**

Purified HSPCs were obtained by the modification of the method described by Davis and colleagues [22]. Briefly, three mice were killed and the femurs and tibias were aseptically removed per experiment (n = 6 separate experiments). Bone marrow cells (BMCs) were flushed from the shaft with wash buffer consisting of Dulbecco’s phosphate-buffered saline supplemented with 2% heat-inactivated fetal calf serum (HyClone, Logan, UT, USA),
and penicillin (100 U/ml) and streptomycin (100 μg/ml) (culture reagents from Invitrogen, Rockville, MD, USA). BMCs were filtered through a nylon-mesh 70 μm cell strainer filter (BD Biosciences, San Diego, CA, USA) to produce a single cell suspension. After washing, BMCs were treated with ACK lysing buffer (NH₄Cl; Invitrogen) and then incubated in a lineage antibody cocktail of biotin-conjugated anti-mouse mAbs specific for CD4, CD8, CD45RA/B220, CD11b, Gr-1 and Ter-119 (Miltenyi Biotec, Auburn, CA, USA) for 15 minutes at 4 to 12°C. After wash and cell resuspension steps, labeled Lin⁺ cells were incubated with anti-biotin magnetic microbeads and depleted by magnetic cell sorting (Miltenyi Biotec). Collected lineage-negative cells (Lin−) were then stained either with rat anti-mouse phycoerythrin (PE)-conjugated CD117 (c-Kit), APC-Cy7-conjugated CD45, fluorescein isothiocyanate (FITC)-conjugated Ly-6A/E (Sca-1) antibodies and PerCP-conjugated streptavidin to detect residual Lin⁺ cells or with control isotype-matched irrelevant mAbs labeled with the corresponding fluorochromes (BD-PharMingen, San Diego, CA, USA). Cell sorting for LKSs was performed using a BD fluorescence-activated cell sorting (BD-PharMingen, San Diego, CA, USA). Reflow analysis of sorted cells to check purity verified that the sorted LKS preparations were 97.1 ± 1.32% pure (n = 6).

Isolation, culture and identification of bone marrow mesenchymal stromal cells

BMMSCs were isolated and cultured using standard protocols [17,23,24]. In brief, erythrocyte-depleted BMCs were plated at a density of 4 × 10⁵ cells/cm² in MesenCult (StemCell Technologies, Vancouver, BC, Canada) supplemented with 100 IU/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Gaithersburg, MD, USA) in a fully humidified atmosphere of 5% CO₂ in air at 37°C. Culture medium was changed after 24 hours to remove non-adherent cells. Fresh medium was subsequently replaced every 3 days. After 7 days, adherent colony-forming cells were trypsinized, harvested, and immunodepleted of FITC-labeled CD11b⁺, CD14⁺ and CD45⁺ cells using anti-FITC magnetic microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. CD45⁻ cells were replated at a density of 5,000 cells/cm², expanded and passaged weekly for an additional 2 to 3 weeks. Cell purity was assessed by FACS analysis using fluorochrome-labeled antibodies against CD3, CD11b, CD14, CD19, CD31, CD34, CD105, CD106, CD133, CD25, CD44, CD45, CD73, CD80, CD86, CD90, Flk-1, c-Kit, Sca-1, MHC class I and MHC class II (PharMingen/Becton Dickinson, San Diego, CA USA). BMMSCs at the time of experimentation were >99% CD45⁻ based on FACS analysis.

Differentiation of bone marrow mesenchymal stromal cells in vitro

Osteogenesis

Osteoblastic differentiation was induced with slight modification of a previously published protocol [23], by culturing confluent BMMSCs for 3 weeks in complete MesenCult medium (StemCell Technologies) supplemented with 10⁻⁸ M dexamethasone, 5 mM β-glycerophosphate, and 50 μg/ml ascorbic acid. All osteogenic supplements were obtained from StemCell Technologies. Cultures were incubated at 37°C in a humidified atmosphere of air with 5% CO₂. Culture medium was exchanged every third day for 3 weeks. Osteogenic differentiation, for secreted calcified extracellular matrix, was detected by Alizarin red staining [23,24].

Adipogenesis

Confluent culture BMMSCs were cultured for 3 weeks in complete MesenCult medium (StemCell Technologies) supplemented with 10⁻⁸ M dexamethasone and 5 μg/ml insulin. All adipogenic supplements were obtained from Sigma-Aldrich (St Louis, MO, USA). Cultures were incubated at 37°C in a humidified atmosphere of air with 5% CO₂. Culture medium was exchanged every third day for 3 weeks. Adipogenesis was detected by Oil red O staining [23,24].

Chondrogenesis

BMMSCs were grown in micromass culture pellets in chondrogenesis induction medium as previously described [25]. Briefly, BMMSCs were seeded as 20 μl drops of (1.6 × 10⁵ cells/drop) onto the center of each well of a six-well culture plate and allowed to attach at 37°C for 2 hours. Subsequently, attached MSC nodules were fed chondrogenic medium containing MesenCult medium (StemCell Technologies) supplemented with 10⁻⁸ M dexamethasone, 6.25 μg/ml insulin, 50 μg/ml ascorbic acid, 1 mM sodium pyruvate, 40 μg/ml proline, 50 ng/ml ITS + Premix (these six reagents purchased from Sigma-Aldrich), and 10 ng/ml transforming growth factor beta-1 (Peprotech, Rocky Hill, NJ, USA). Cultures were incubated at 37°C in a humidified atmosphere of air with 5% CO₂. Culture medium was exchanged every third day for 3 weeks. Chondrogenic differentiation was detected by Alcian blue staining (Sigma-Aldrich).

RNA extraction

Total RNA was extracted from freshly isolated bone marrow-derived HSPCs (LKSs) and in vitro cultured BMMSCs (passage 2 to 3) as previously described [26]. Briefly, pelleted cells from six independent experimental samples were isolated from pooled BMCs collected from three individual mice. Pelleted cells for each sample were homogenized in Trizol reagent (Invitrogen, Carlsbad, CA, USA) and total RNA was isolated using the standard...
trizol–chloroform–ethanol extraction procedure. RNA's were resuspended in 15 μl of 10 mM Tris buffer, pH 7.5. Sample purity, quantity, and quality were assessed by determining the A260/280 and A260/230 ratios on a Nanodrop Spectrophotometer (NanDrop Technologies Inc., Wilmington, DE, USA) and by measuring the 28S/18S ribosomal RNA ratio and RNA Integrity Number using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA). All Agilent RNA integrity values were ≥8.5. Reverse transcription was performed with a Roche 1st Strand Synthesis kit (Roche Diagnostics Corporation, Indianapolis, IN, USA). Briefly, 2.5 μg RNA sample was added to a master mix containing 1× reaction buffer, 5 mM MgCl₂, 1 mM deoxynucleotide mix, 6.4 μg random primers, 100 units RNase inhibitor, and 40 units AMV reverse transcriptase. Then 10 mM Tris buffer, pH 7.5, was used to reach the 40 μl final reaction volume. The final reaction mixture was then subjected to a single reverse-transcription cycle of 25°C for 10 minutes, 42°C for 60 minutes, 99°C for 5 minutes, and 4°C for at least 10 minutes.

Real-time quantitative PCR gene profiling for cell signaling mRNA transcripts
qRT-PCR was performed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Custom-designed Protein Tyrosine Kinase TaqMan® Low Density Array cards (Applied Biosystems) were used to assess gene expression of key transcripts for RTKs, non-RTKs, cytokine-growth receptors, G-protein coupled receptors, and several other cell signaling molecules. Gene targets were selected based on an extensive review of the literature for well-validated gene expression markers and the availability of Assay of Demand commercial primers (Applied Biosystems). The set of TaqMan® Low Density Array cards was comprised of 96 individual target assays (including respective forward and reverse primers and a dual-labeled probe (5′-6-FAM; 3′-MGB) in quadruplicate on a 384-well card (96 genes per card including two housekeeping genes, 18S and GAPDH). Amplification parameters were as follows: one cycle of 50°C for 2 minutes and 95°C for 10 minutes followed by 40 cycles of 95°C for 30 seconds and 60°C for 1 minute.

RT-PCR data analysis
RT-PCR data were analyzed using the Sequence Detection System version 2.1 included with the ABI Prism 7900HT SDS and Microsoft Excel. The threshold was manually set and the baseline was set automatically to obtain the threshold cycle (Cₜ) value for each target. 18S ribosomal RNA was used as an endogenous housekeeping control gene for normalization. Six independent HSPC and BMMSC experimental samples were run in duplicate wherein Cₜ measurements per samples were normalized using 18S. Relative expression between HSPCs and BMMSCs was determined using the comparative Cₜ method (2⁻ΔΔCₜ) [27,28]. Results are expressed as the mean ± standard deviation difference in relative expression. Transcription of a particular gene transcript in BMMSCs was considered to be differentially upregulated or down-regulated if it was differentially expressed by at least twofold when compared with the expression level in HSPCs, and vice versa for the reverse analysis. Assays with Cₜ values greater than 35 cycles were excluded from analysis.

Validation of qRT-PCR results using FACS analysis for cell surface protein expression
LKSs (HSPCs) and BMMSCs were stained with rat anti-mouse CD45-PE/FITC, Sca-1-PE, c-Kit-FITC, and Flk1-PE (PharMingen/Becton Dickinson) or rabbit polyclonal anti-human DDR2 (H-108, cross-reacts with mouse), rat anti-mouse PDGFR-α (RM0004-3G28; Santa Cruz Biotechnology, Santa Cruz, CA, USA), primary antibodies followed by PE-labeled goat anti-rabbit and goat anti-rat secondary antibodies, respectively (PharMingen/Becton Dickinson).

Statistical analyses
For each mRNA measured in qRT-PCR, replicate Cₜ values for six biological samples were averaged to obtain the mean and standard error of the mean. A paired two-tailed t test (analysis of variance) was performed to determine whether the expression was different between the HSPCs and BMBMCs. Individual genes were identified as differentially expressed with ≥2-fold difference between cell types and P ≤0.05. Data were analyzed using GraphPad Prism version 4.01 (GraphPad Software, San Diego, CA, USA).

Results
Bone marrow-derived HSPC and MSC populations
To obtain accurate and consistent gene transcription profiles of bone marrow-derived HSPC and MSC populations, we isolated and used highly purified cell populations. Practically all HSPC activity has been shown to be contained within the LKS BMC compartment, which represents 0.05 to 0.1% of total BMCs [29]. LKS cells were isolated by lineage-negative selection (pooled bone marrow from three mice, n = 6 separate experiments) followed by double FACS sorting to high purities (98 ± 1.32%; Figure 1A-D). Total RNA from a total of six individual LKS samples was extracted to conduct qRT-PCR gene profiling for cell signaling transcripts in duplicate using a custom-designed Cell Signaling TaqMan® Low Density Array. For each mRNA measured in qRT-PCR, gene expression values were averaged across six biological samples run in technical replicates.

Plastic adherent bone marrow stromal cells were isolated from pooled bone marrow from three mice, propagated for 1 week, hematopoietic cell depleted, and expanded further in vitro for 2 to 3 weeks, at which time they reached a
stable MSC phenotype by FACS analysis (Figure 2) positive for known stromal–mesenchymal markers such as CD44, CD73, CD90, CD105, and MHC class I and negative for the hematopoietic cell lineage markers including CD45, CD11b, CD14, CD34, MHC class II and CD31. BMMSCs expressed low levels of CD106, Flk-1 and CD133 and were negative for CD3, CD25, CD19, c-Kit (CD117) and for costimulatory molecules CD80 and CD86 (data not shown). To establish that these cells are true MSCs, cells were cultured under various induction conditions to assess their capacity to differentiate into a number of mesodermal lineages. As illustrated in Figure 3, BMMSCs display a multilineage differentiation capacity toward the adipogenic, osteogenic and chondrogenic cell lineages.

**Expression profile of receptor tyrosine kinase genes**

To compare gene expression levels within purified HSPC and BMMSC populations, RNA samples from six separate pooled experimental samples were prepared and key transcripts for RTKs, non-RTKs, cytokine-growth receptors, G-protein coupled receptors, and several other cell signaling molecules were assayed in duplicate using qRT-PCR. In rodents, 58 RTKs have been identified. In our study, 37 primer/probe sets for RTK transcripts were included in a customized TaqMan® gene expression array card of total 96 genes (Table 1). Out of these 37 RTK genes, only Aatk (apoptosis associated tyrosine kinase) and Csf1r (colony-stimulating factor 1 receptor) were over expressed, 2.5-fold and 197-fold respectively, in HSPCs in comparison with BMMSCs. In contrast to HSPCs, transcripts for 13 RTK genes (Axl, Mertk, Tyro3, Epha1, Epha2, Epha4, Ephb4, Egfr, Fgfr1, Pdgfrb, Met and Ret) were overexpressed 3-fold to 819-fold in BMMSCs. Four RTK transcripts uniquely expressed by HSPCs were Flt3 (FMS-like tyrosine kinase 3), Kit (kit oncogene), Tek (endothelial-specific RTK) and Tie1, whereas Ddr1, Ddr2, Epha3, Ephb3, Fgrfr2, Fgrfr3, Pdgfra, Mst1r, Ror1 and Ror2 were identified as 10 BMMSC-specific RTK genes. RTK transcripts for Insr (insulin receptor), Flt1 (FMS-like tyrosine kinase 1) and Kdr (kinase insert domain protein receptor) were generally equally expressed in HSPCs and BMMSCs, whereas transcripts for five RTK genes (Epha6, Epha8, Musk, Ros1 and Ntrk2) were not detectable in either HSPCs or BMMSCs.

**Expression profile of cytoplasmic non-tyrosine kinase genes**

Out of 32 murine non-RTK genes, we included 23 genes in our present study (Table 1). Among the non-RTK genes evaluated, 10 genes (Btk, Tec, Hck, Lck, Lyn, Jak2, Jak3,
Matk, Fes, and Syk) were upregulated by twofold to 972-fold in HSPCs in comparison with BMMSCs and five non-RTK genes (AbI1, Fert2, Fyn, Ptk2, and Tnk2) were overexpressed threefold to 47-fold in BMMSCs. Moreover, four non-RTK genes (Bmx, Txx, Fgr and Zap70) were found to be exclusively expressed in HSPCs. Fyn was only detectable in BMMSCs, while Jak1 was similarly expressed in HSPCs and BMMSCs. Transcripts for the non-RTK genes Tnk1 and Srms were not detectable in either HSPCs or BMMSCs.

Expression profile of G-protein coupled receptor genes

G-protein coupled receptors comprise a large protein family of transmembrane receptors that transduce extracellular stimuli into intracellular signals through their interaction with heterotrimeric G proteins [30]. All 19 distinct mammalian chemokine receptors are the members of the large protein family G-protein coupled receptors [31]. We analyzed 10 G-protein coupled receptor transcripts, including eight chemokine receptors (Ccr1, Ccr3, Ccr4, Ccr7, Ccr8, Cxcr3, Cxcr5 and Cxcr7), in our custom-designed gene expression array profile (Table 1). Ccr1 was expressed 96-fold more in HSPCs than in BMMSCs, and gene transcripts for Ccr8 and CmKor1 (Cxcr7) were upregulated fourfold and 293-fold respectively in BMMSCs when compared with HSPCs. Expression of Ccr4, Ccr7, Cxcr3 and Blr1 (Cxcr5) were limited to HSPCs, while transcript expression for Ccr3, Agtr1 (angiotensin receptor-like 1) and Ednrβ (endothelin receptor type B) were similarly expressed in both HSPCs and BMMSCs.

Expression profile of cytokine receptor genes

Cytokine receptors are transmembrane receptors expressed on the surface of a wide range of cells that recognize and respond to cytokines; however, cytokine receptors lack intrinsic protein tyrosine activity found in many other receptors [32]. Signaling through cytokine receptors depends upon their interaction with Janus kinases, which couple ligand binding to tyrosine phosphorylation of signaling recruited to the receptor complex [33]. Fifteen members of the type-1 cytokine receptor family (CRF1) mostly comprising the hematopoietin cytokine receptors (Il3ra, Il6ra, Il7r, Csflra, Csf2rb, Csf3r, Epor, Osnn, Lifr, Mpl, Ngfr, Tnfrsf1a, Acvr1, Acvr1I and Bmpr1a) were included in our differential gene expression assessment. Out of these 15 cytokine receptor genes, Il6ra, Il7r, Csf2ra and Epor were upregulated in HSPCs by fourfold, 156-fold, 25-fold and 12-fold respectively when compared with transcript expression levels in BMMSCs (Table 1). Acvr1, Acvr1I, Bmpr1a and Lifr were
overexpressed by 22-fold, 3-fold, 6-fold and 2-fold more in MSCs. Csf2rb, Csf3r and Mpl were exclusively expressed in HSPCs. Ngfr and Osmr expression was restricted to MSCs, and IL3ra and Tnfrsf1a were similarly expressed in both HSPCs and BMMSCs.

**Expression profile of transcripts for other cell signaling molecules**

A few other cell signaling targets genes were evaluated and were differentially expressed in HSPC and BMMSC populations (Table 1). Transcript expression of the leukocyte common antigen (PTPRC/CD45) was restricted to HSPCs. Genes transcripts for Mrc1 (mannose receptor, C type 1) and Lgals9 (lectin, galactose binding, soluble 9) were overexpressed in HSPCs by 2.5-fold and 19-fold respectively in comparison with the transcript levels in BMMSCs (Table 1), while Gas6 (growth arrest specific 6), Sca1 (spino cerebellar ataxia 1), and Spp1 (secreted phosphoprotein-1) expression levels were significantly higher, 381-fold, 3-fold, and 425-fold respectively, in BMMSCs. Furthermore, Gata4 (GATA binding protein 4), a transcription factor, was exclusively expressed in BMMSCs, whereas the expression levels of the transcription factor Hoxb4 (homeobox B4) and Abcb1b (ATP-binding cassette, sub-family B (MDR/TAP), member 1B) were similar in both HSPCs and BMMSCs.

**Flow cytometry validation of RT-PCR array data**

To validate the results obtained by qRT-PCR microarray analysis, we selected six target genes that are differentially expressed and assessed their comparative expression corresponding cell surface protein levels using flow cytometric analysis (Figure 4). Our mRNA transcript results demonstrate the receptors for collagen (Ddr2) and platelet-derived growth factor (Pdgfra) were exclusively expressed only on BMMSCs that lack c-kit and CD45 expression (Figure 2), whereas both populations of cells expressed transcripts and cell surface protein for Sca-1 and KDR (Flk-1/Vegfr2).

**Discussion**

Bone marrow HSPCs and BMMSCs share a common microenvironmental niche wherein intercellular and intracellular network signaling communications direct stem cell fate activation, proliferation, development, and tissue differentiation [34,35]. Limited comparative information is available on the molecular signaling behavior of undifferentiated BMMSCs and HSPCs. Defining the signaling mechanisms expressed in adult undifferentiated stem cells is an essential step toward understanding the developmental and regenerative capabilities. Here we report a comprehensive evaluation, of mRNA gene transcripts for 94 signaling molecules, in which 11 transcripts were equally expressed in both HSPCs and BMMSCs, 19 overexpressed in HSPCs compared with BMMSCs, 27 overexpressed in BMMSCs compared with HSPCs, 16 expressed only in HSPCs, 14 expressed only in BMMSCs and seven expressed in neither cell population. To our knowledge, this is the first study to report simultaneous determination of multiple cell signaling molecules in highly purified undifferentiated stem cell populations under standardized conditions. Flow cytometric analysis showed that the transcriptional levels of CD45, c-kit, Sca-1, KDR (Flk-1/Vegfr2), Pdgfra, and Ddr2 were consistent with the cell surface translational levels of protein expression.

Of the 90 PTKs, 58 are categorized as RTKs and 32 as cytoplasmic non-RTKs [14]. Of the 37 RTK gene transcripts we evaluated, 23 gene transcripts were either exclusively confined to or more highly expressed in BMMSCs. Transcripts for Aatk, and Csfr1 were more highly expressed in HSPCs than in BMMSCs, while transcripts Flt3, Kit, Tek, and Tie1 were found to be exclusively expressed in HSPCs, all known receptors for ligands that have been shown to be important in primitive HSPC survival, quiescence, activation, proliferation, mobilization and/or differentiation [36-41]. In contrast, we found in BMMSCs a different set of transcripts for genes encoding signaling receptors linked to stem cell survival and growth (Axl, Pdgfr and Egfr), self-renewal (Egfr and Ephr), maintenance
### Table 1 Differential gene expression between bone marrow-derived hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells

| Gene identification                        | Assay on demand | ΔCt^HSPC | ΔCt^BMMSC | Fold-change HSPC/BMMSC | P value |
|-------------------------------------------|-----------------|----------|-----------|------------------------|---------|
| **RTK gene transcripts**                  |                 |          |           |                        |         |
| Aatk—apoptosis-associated tyrosine kinase | Mm00545697_m1   | 16.8 ± 0.57 | 17.91 ± 0.30 | 2.5                    | 0.009   |
| Axl—AXL receptor tyrosine kinase          | Mm00437221_m1   | 21.03 ± 0.41 | 11.49 ± 0.32 | −818.7                 | 0.0001  |
| Mertk—c-mer proto-oncogene tyrosine kinase| Mm00434920_m1   | 23.04 ± 0.76 | 16.86 ± 0.41 | −21.7                  | 0.0001  |
| Tyro3—TYRO3 protein tyrosine kinase 3     | Mm00444547_m1   | 21.49 ± 0.62 | 15.83 ± 0.38 | −52                    | 0.0001  |
| Ddr1—discoidin domain receptor family, member 1 | Mm00432251_m1 | ND          | 21.20 ± 0.49 |                        |         |
| Ddr2—discoidin domain receptor family, member 2 | Mm0045615_m1 | ND          | 11.46 ± 1.94 |                        |         |
| Egfr—epidermal growth factor receptor     | Mm00433223_m1   | 23.44 ± 0.64 | 16.89 ± 0.48 | −88.8                  | 0.0001  |
| Epha1—Eph receptor A1                     | Mm0045804_m1    | 23.88 ± 0.83 | 20.73 ± 0.42 | −9.2                   | 0.0001  |
| Epha2—Eph receptor A2                     | Mm00438726_m1   | 19.20 ± 0.96 | 17.34 ± 0.46 | −3.8                   | 0.0001  |
| Epha3—Eph receptor A3                     | Mm00580743_m1   | ND          | 22.18 ± 0.33 |                        |         |
| Epha4—Eph receptor A4                     | Mm00433056_m1   | 22.17 ± 0.49 | 20.76 ± 0.41 | −28                    | 0.0001  |
| Epha6—Eph receptor A6                     | Mm00433094_m1   | ND          | ND          |                        |         |
| Epha7—Eph receptor A7                     | Mm00833876_m1   | 22.06 ± 1.10 | 17.57 ± 0.29 | −22.9                  | 0.0001  |
| Epha8—Eph receptor A8                     | Mm00431306_m1   | ND          | ND          |                        |         |
| Ephb3—Eph receptor B3                     | Mm00802553_m1   | ND          | 16.69 ± 0.79 |                        |         |
| Fgfr1—fibroblast growth factor receptor 1 | Mm00438923_m1   | 20.91 ± 1.27 | 15.95 ± 0.20 | −36.5                  | 0.0001  |
| Fgfr2—fibroblast growth factor receptor 2 | Mm0043941_m1    | ND          | 20.55 ± 0.40 |                        |         |
| Fgfr3—fibroblast growth factor receptor 3 | Mm00433294_m1   | ND          | 20.32 ± 0.48 |                        |         |
| Insr—insulin receptor                     | Mm00439693_m1   | 15.97 ± 0.43 | 15.82 ± 0.29 | −1.1                   | 0.3273  |
| Met—met proto-oncogene                    | Mm00439492_m1   | 18.25 ± 0.38 | 14.36 ± 0.49 | −15.9                  | 0.0001  |
| Mst1r—macrophage stimulating 1 receptor (c-met-related tyrosine kinase) | Mm00436365_m1 | ND          | 24.49 ± 1.08 |                        |         |
| Musk—muscle, skeletal, receptor tyrosine kinase | Mm00448006_m1 | ND          | ND          |                        |         |
| Csf1r—colony stimulating factor 1 receptor | Mm00432689_m1   | 14.89 ± 0.43 | 22.45 ± 0.43 | 197.3                  | 0.0001  |
| Flt3—FMS-like tyrosine kinase 3           | Mm00438996_m1   | 17.68 ± 0.87 | ND          |                        |         |
| Kit—kit oncogene                          | Mm00445212_m1   | 15.21 ± 0.63 | ND          |                        |         |
| Pdgfα—platelet derived growth factor receptor, alpha polypeptide | Mm00440701_m1 | ND          | 16.71 ± 0.66 |                        |         |
| Pdgfrβ—platelet derived growth factor receptor, beta polypeptide | Mm00435546_m1 | 19.98 ± 0.60 | 13.83 ± 0.24 | −72.4                  | 0.0001  |
| Ret—ret proto-oncogene                    | Mm00436304_m1   | 22.27 ± 0.64 | 20.56 ± 0.41 | −3.4                   | 0.0001  |
| Ror1—receptor tyrosine kinase-like orphan receptor 1 | Mm00443462_m1 | ND          | 18.75 ± 0.37 |                        |         |
| Ror2—receptor tyrosine kinase-like orphan receptor 2 | Mm00443470_m1 | ND          | 19.22 ± 0.30 |                        |         |
| Ros1—Ros1 proto-oncogene                  | Mm00803362_m1   | ND          | ND          |                        |         |
| Tek—endothelial-specific receptor tyrosine kinase | Mm00443242_m1 | 18.52 ± 1.21 | ND          |                        |         |
| Tiel1—tyrosine kinase receptor 1          | Mm00441786_m1   | 20.39 ± 0.84 | ND          |                        |         |
| Ntrk2—neurotrophic tyrosine kinase, receptor, type 2 | Mm00435422_m1 | ND          | ND          |                        |         |
| Flt1—FMS-like tyrosine kinase 1           | Mm00439890_m1   | 21.13 ± 0.41 | 20.52 ± 0.49 | −1.6                   | 0.0032  |
| Kdr—kinase insert domain protein receptor | Mm00440099_m1   | 23.48 ± 0.60 | 23.31 ± 0.70 | −1.3                   | 0.5296  |
| **Non-RTK transcripts**                   |                 |          |           |                        |         |
| Ab1—v-abl Abelson murine leukemia oncogene 1 | Mm00802038_g1  | 16.54 ± 0.54 | 14.93 ± 0.14 | −3                    | 0.0001  |
| Tnk1—tyrosine kinase, non-receptor, 1     | Mm00840782_g1   | ND          | ND          |                        |         |
| Tnk2—tyrosine kinase, non-receptor, 2     | Mm00450301_m1   | 17.25 ± 0.34 | 15.88 ± 0.25 | −2.6                   | 0.0001  |
| Matk—megakaryocyte-associated tyrosine kinase | Mm00440268_m1 | 17.49 ± 0.83 | 22.68 ± 0.58 | 41.9                   | 0.0001  |
Table 1 Differential gene expression between bone marrow-derived hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells (Continued)

| Gene Name                  | RefGene ID | Condition 1 | Condition 2 | log2 Fold | p-value |
|----------------------------|------------|-------------|-------------|-----------|---------|
| Ptk2-PTK2 protein tyrosine kinase 2 | Mn00433209_m1 | 20.21 ± 0.90 | 14.67 ± 0.28 | -47.1 | 0.0001 |
| Fer2-fer (fms/fps related) protein kinase, testis specific 2 | Mn00484303_m1 | 17.74 ± 0.48 | 15.11 ± 0.22 | -6.3 | 0.0001 |
| Fes-feline sarcoma oncogene | Mn00802572_g1 | 13.51 ± 0.47 | 17.67 ± 0.45 | 18.8 | 0.0001 |
| Frk-fyn-related kinase | Mn00456656_m1 | ND | 18.56 ± 0.54 |  |  |
| Srmssrc-related kinase lacking C-terminal regulatory tyrosine | Mn00441546_m1 | ND | ND |  |  |
| Jak1-Janus kinase 1 | Mn00600614_m1 | 13.23 ± 0.54 | 12.47 ± 0.43 | -1.8 | 0.0009 |
| Jak2-Janus kinase 2 | Mn00434561_m1 | 14.69 ± 0.63 | 15.81 ± 0.25 | 2.4 | 0.0001 |
| Jak3-Janus kinase 3 | Mn00439962_m1 | 16.78 ± 0.62 | 17.93 ± 0.20 | 2.4 | 0.0001 |
| Fgr-Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog | Mn00438949_m1 | 14.67 ± 1.61 | ND |  |  |
| Fyn-Fyn proto-oncogene | Mn00433373_m1 | 17.01 ± 0.54 | 14.57 ± 0.40 | -5.6 | 0.0001 |
| Hck-hemopoietic cell kinase | Mn00439302_m1 | 14.2 ± 0.76 | 22.11 ± 0.54 | 275.1 | 0.0001 |
| Lck-lymphocyte protein tyrosine kinase | Mn00802897_m1 | 19.42 ± 0.49 | 23.04 ± 0.43 | 13 | 0.0001 |
| Lyn-Yamaguchi sarcoma viral (v-yes-1) oncogene homolog | Mn00802933_m1 | 13.28 ± 0.87 | 19.56 ± 0.51 | 93.1 | 0.0001 |
| Bmx-BMX non-receptor tyrosine kinase | Mn00515368_m1 | 14.73 ± 1.07 | ND |  |  |
| Btk-Bruton agammaglobulinemia tyrosine kinase | Mn00442712_m1 | 15.05 ± 1.20 | 29.92 ± 0.76 | 972.4 | 0.0001 |
| Tec-cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) | Mn00443230_m1 | 16.2 ± 0.34 | 18.24 ± 0.33 | 4.2 | 0.0001 |
| Txk-TXK tyrosine kinase | Mn00443280_m1 | 20.98 ± 0.50 | ND |  |  |
| Syk-spleen tyrosine kinase | Mn00441649_m1 | 12.74 ± 0.57 | 17.10 ± 0.21 | 22.1 | 0.0001 |
| Zap70-zeta-chain (TCR) associated protein kinase | Mn00494255_m1 | 19.49 ± 1.30 | ND |  |  |
| G-protein coupled receptor transcripts |  |  |  |  |  |
| Agtrl1-angiotensin receptor-like 1 | Mn00442191_s1 | 19.96 ± 0.56 | 20.22 ± 0.88 | 1.3 | 0.3972 |
| Ednrb-endothelin receptor type B | Mn00432989_m1 | 22.96 ± 1.06 | 22.70 ± 0.67 | 1 | 0.4802 |
| Ccr1-chemokine (C-C motif) receptor 1 | Mn00438260_s1 | 13.33 ± 0.63 | 19.78 ± 1.13 | 95.6 | 0.0001 |
| Ccr3-chemokine (C-C motif) receptor 3 | Mn00515543_s1 | 19.93 ± 0.36 | 20.03 ± 1.10 | 1.1 | 0.7675 |
| Ccr4-chemokine (C-C motif) receptor 4 | Mn00438271_m1 | 23.9 ± 1.24 | ND |  |  |
| Ccr7-chemokine (C-C motif) receptor 7 | Mn00432608_m1 | 18.32 ± 1.50 | ND |  |  |
| Ccr8-chemokine (C-C motif) receptor 8 | Mn00843415_s1 | 21.55 ± 0.44 | 19.71 ± 0.83 | -4.1 | 0.0001 |
| Cxcr3-chemokine (C-X-C motif) receptor 3 | Mn00438259_m1 | 20.74 ± 0.36 | ND |  |  |
| Btkl (Cxcr5)-Burkitt lymphoma receptor 1 | Mn00432086_m1 | 20.88 ± 1.00 | ND |  |  |
| Cmkor1 (Cxcr7)-chemokine orphan receptor 1 | Mn00432610_m1 | 23.68 ± 1.01 | 15.52 ± 0.35 | -293.2 | 0.0001 |
| Cytokine receptor transcripts |  |  |  |  |  |
| Acvr1-activin A receptor, type 1 | Mn00431645_m1 | 17.98 ± 0.83 | 13.57 ± 0.45 | -22.2 | 0.0001 |
| Acvr1-activin A receptor, type II-like 1 | Mn00437432_m1 | 20.73 ± 0.60 | 19.32 ± 0.67 | -2.9 | 0.0001 |
| Bmpr1a-bone morphogenetic protein receptor, type 1A | Mn00477650_m1 | 17.28 ± 0.95 | 14.75 ± 0.22 | -5.9 | 0.0001 |
| Il3ra-interleukin 3 receptor, alpha chain | Mn00434273_m1 | 18.52 ± 0.53 | 18.40 ± 0.44 | -1.1 | 0.5524 |
| Il6ra-interleukin 6 receptor, alpha | Mn00439653_m1 | 14.54 ± 0.38 | 16.40 ± 0.51 | 3.8 | 0.0001 |
| Il17r-interleukin 7 receptor | Mn00434295_m1 | 17.11 ± 0.24 | 24.38 ± 0.75 | 155.9 | 0.0001 |
| Csf2ra-colony stimulating factor 2 receptor, alpha | Mn00438331_g1 | 14.46 ± 0.40 | 19.04 ± 0.22 | 24.9 | 0.0001 |
| Csf2rb2-colony stimulating factor 2 receptor, beta 2 | Mn00655763_m1 | 17.33 ± 0.38 | ND |  |  |
| Csf3r-colony stimulating factor 3 receptor | Mn00432735_m1 | 11.85 ± 1.43 | ND |  |  |
| Epor-erythropoietin receptor | Mn00833882_m1 | 19.42 ± 1.07 | 22.59 ± 0.85 | 11.6 | 0.0001 |
| Lifr-leukemia inhibitory factor receptor | Mn00442940_m1 | 17.89 ± 0.64 | 16.76 ± 0.36 | -2.3 | 0.0001 |
| Mpl-myeloproliferative leukemia virus oncogene | Mn00440310_m1 | 14.86 ± 1.69 | ND |  |  |
| Ngfr-nerve growth factor receptor (TNFR superfamily, member 16) | Mn00446294_m1 | ND | 11.96 ± 0.30 |  |  |
of stem cells in the dedifferentiated state (Egfr, Fgfr), and recruitment of cells to injured tissue (Met, Mst1R, and Pdgfr) [42-47]. Furthermore signaling molecules that modulate osteogenesis/chondrogenesis (Ror1, Ror2, Ddr1, and Ddr2) and neuronal cell development (Ret) were either exclusively or differentially expressed in BMMSCs. We show transcription of Gas6, a secreted vitamin-K-dependent protein ligand for Axl, Mertk, and Tyro3 known to play a role in reversible cell growth arrest, survival, proliferation, cell adhesion, long-term hematopoiesis, and erythropoiesis [48-50]. Other signaling molecules that regulate transcripts are known to be important in early HSPC niche where they support HSPC survival (anti-apoptotic action) and quiescence [53]. Furthermore, we found that the expression of G-protein chemokine receptors for the cell trafficking molecules MIP-1, RANTES, TARC, and MCP-1 (Ccr4), MIP-3β (Ccr7) and IP-10, I-TAC and Mig (Cxcr3) is exclusive in HSPCs. These data suggest and are consistent with the notion that quiescent HSPCs are poised for mobilization.

Consistent with the RTK and non-RTK findings, HSPCs were notably enriched in Tec kinases (Tec, Btk, Bmx, and Ttk), SRC kinases (Fgr and Lck), SFK kinases (Hck), Syk  kinases (Syk and Zap-70), Janus kinase/STAT kinases (Jak2 and Jak3) and c-fes kinases (Fes). These intracellular regulated transcripts are known to be important in early HSPC decisions, and may play a key role in HSPC self-renewal, quiescence and lineage-specific differentiation. In contrast, BMMSCs expressed higher transcript levels of Ab11, Fert2, Fyn Ptk2, Tnk2, and Frk, which have been shown in other cell types to have cytoplasmic and/or nuclear regulatory functions in during cell differentiation, cell remodeling, cell division, cell adhesion and cell migration [54-59]; however, their roles in BMMSCs are unknown and further evaluation is needed.

Our findings in this report are subject to several limitations. First, we compared cell signaling receptors of cultured early passaged BMMSCs to freshly isolated HSPCs. It is possible that some of the differential expression in these genes is solely due to the fact that BMMSCs were cultured whereas the HSPCs were not. This may account for an over-representation of RTKs in BMMSCs compared with HSPCs. Second, it is accepted BMMSCs were cultured whereas the HSPCs were not. This may account for an over-representation of RTKs in BMMSCs compared with HSPCs. Second, it is accepted

| Other signaling molecule transcripts | Other signaling molecule transcripts |
|-------------------------------------|-------------------------------------|
| Abcb1b-ATP-binding cassette, sub-family B (MDR/TAP), member 1B | Abcb1b-ATP-binding cassette, sub-family B (MDR/TAP), member 1B |
| Mcl1-mannose receptor, C type 1 | Mcl1-mannose receptor, C type 1 |
| Gata4-GATA binding protein 4 | Gata4-GATA binding protein 4 |
| Hoxb4-homeo box B4 | Hoxb4-homeo box B4 |
| Ptprc-protein tyrosine phosphatase, receptor type, C | Ptprc-protein tyrosine phosphatase, receptor type, C |
| Gas6-growth arrest specific 6 | Gas6-growth arrest specific 6 |
| Lgals9-lectin, galactose binding, soluble 9 | Lgals9-lectin, galactose binding, soluble 9 |
| Scalin-scamporebellin ataxia 1 homolog (human) | Scalin-scamporebellin ataxia 1 homolog (human) |
| Spp1-secreted phosphoprotein 1 | Spp1-secreted phosphoprotein 1 |

Table 1 Differential gene expression between bone marrow-derived hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells (Continued)

| Gene | Gene differential expression was considered significant with P <0.05. Mean ± standard deviation of six independent HSPC and BMMSC preparations are shown. BMMSC, bone marrow-derived mesenchymal stromal cell; Ct, cycle threshold; HSPC, hematopoietic stem/progenitor cell; ND, not detectable; RTK, receptor tyrosine kinase. *Quantitative PCR was performed on an ABI PRISM 7900HT Sequence Detection System using a custom-made TaqMan® Low Density Array. mRNA transcripts were evaluated with TaqMan® Probes commercially available as Assay on Demand (Applied Biosystems, Foster City, CA, USA) with optimized primer and probe concentrations. 

| Gene | Gene | Gene | Gene | Gene |
|------|------|------|------|------|
| Osmr-oncostatin M receptor | Mm00495424_m1 | ND | 15.97 ± 0.24 | 1.4 | 0.0023 |
| Tnfsf1a-tumor necrosis factor receptor superfamily, member 1a | Mm0041875_m1 | 13.49 ± 0.36 | 13.91 ± 0.24 | 1.4 | 0.0023 |
| Abcb1b-ATP-binding cassette, sub-family B (MDR/TAP), member 1B | Mm00440736_m1 | 18.64 ± 0.64 | 17.73 ± 0.38 | −1.9 | 0.0003 |
| Mcl1-mannose receptor, C type 1 | Mm00485148_m1 | 20.76 ± 0.47 | 22.00 ± 0.62 | 2.5 | 0.0001 |
| Gata4-GATA binding protein 4 | Mm00494689_m1 | ND | 20.10 ± 0.31 | ND | ND |
| Hoxb4-homeo box B4 | Mm00657964_m1 | 17.88 ± 0.50 | 17.28 ± 0.59 | −1.7 | 0.0134 |
| Ptprc-protein tyrosine phosphatase, receptor type, C | Mm00484663_m1 | ND | ND | ND | ND |
| Gas6-growth arrest specific 6 | Mm00490378_m1 | 23.45 ± 1.02 | 14.90 ± 0.26 | −381.1 | 0.0001 |
| Lgals9-lectin, galactose binding, soluble 9 | Mm00495295_m1 | 13.67 ± 0.82 | 17.69 ± 0.25 | 18.9 | 0.0001 |
| Scalin-scamporebellin ataxia 1 homolog (human) | Mm00485928_m1 | 17.08 ± 0.23 | 15.71 ± 0.29 | −2.6 | 0.0001 |
| Spp1-secreted phosphoprotein 1 | Mm00493767_m1 | 17.91 ± 0.33 | 9.23 ± 0.44 | −424.9 | 0.0001 |
that *in vivo* conditions are different from the *in vitro* experimental culture conditions wherein most of the niche microenvironmental conditions are absent. Third, gene expression is under regulatory control at many different stages, and therefore it is difficult to equate mRNA levels with gene expression levels. Fourth, future studies are needed to determine the signaling profiles during times of stress, injury, inflammation or repair. Lastly, the gene expression data generated and the conclusions need to be verified *in situ* in localized cells at specific anatomic sites using immunochemistry and laser capture microdissection or other techniques [60].

**Conclusion**

In this study, we conducted a comparative analysis of gene transcripts for a number of cell signaling receptors in highly purified undifferentiated HSPCs and BMMSCs. Clearly the expression of a number of these genes overlaps between HSPCs and BMMSCs, but comparative analysis of the gene profiles showed that there are a substantial number of gene transcripts that are distinct or more highly expressed in specific stem cell populations. Evaluating and characterizing the role of these genes in regulating stem behavior in terms of cell quiescence, proliferative capacity, mobility and differentiation potential will be critical to

---

**Figure 4** Cell surface protein expression on undifferentiated hematopoietic stem/progenitor cells and bone marrow-derived mesenchymal stromal cells. Cell surface expression of CD45, c-Kit, Sca-1, Kdr (Flk1/Vegfr2), Ddr2 and Pdgfra on undifferentiated Lin-c-Kit+Sca-1 cells (hematopoietic stem/progenitor cells (HSPCs)) and bone marrow-derived mesenchymal stromal cell (BMMSCs; passage 2) via flow cytometric analysis. Unfilled curve, cells stained with isotype control antibody; filled gray curve, staining against each specific protein.
better understanding the developmental and regenerative capabilities of HSPCs and BMMSCs and their potential application in cell-based therapies. A network analysis of RTKs differentially expressed by BMMSCs and of non-RTKs differentially expressed by HSPCs could yield insights into the mechanisms for phosphoprotein networks used by these cells. This information could be potentially valuable for designing media for the efficient expansion of these cells or understanding mechanisms that BMMSCs use to regulate HSPC growth and survival.

Abbreviations

BMC: Bone marrow cell; BMMSC: Bone marrow-derived mesenchymal stromal cell; Ct: Threshold cycle; FACS: Fluorescence-activated cell sorting; FITC: Fluorescein isothiocyanate; HSPC: Hematopoietic stem/ progenitor cell; LKS: Lineage-negative, c-Kit-positive, Sca-1-positive cell; mAb: Monoclonal antibody; MSC: Mesenchymal stromal cell; PE: Phycocerythrin; RTK: Protein tyrosine kinase; qRT-PCR: Quantitative real-time polymerase chain reaction; RTK: Receptor tyrosine kinase; RT-PCR: Reverse transcription polymerase chain reaction.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

KA designed and performed the experiments, collected and analyzed the data, and assisted in the writing of the manuscript. TAD conceived the study, designed the custom low-density array targets and gene target selections, and supervised the study, including experiment design, data analysis, and writing of the manuscript. Both authors read and approved the final manuscript.

Authors’ information

The authors are employees of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that ‘Copyright protection under this title is not available for any work of the United States Government.’ Title 17 U.S.C. §101 defined a US Government work as a work prepared by a military service member or employees of the US Government as part of that person’s official duties. The opinions or assertions contained in this paper are the private views of the authors and are not to be construed as reflecting the views, policy or positions of the Department of the Navy or Army, Department of Defense nor the US Government. The views expressed in this paper are the private views of the authors and are not to be construed as reflecting the views, policy or positions of the Department of the Navy or Army, Department of Defense nor the US Government.

Acknowledgements

The authors thank Doug Smoot for technical expertise in FACS analysis and cell sorting. This work was supported by Naval Medical Research Center I LR grant 6011.52 N05580.2130.A0704.

Received: 21 June 2013 Revised: 26 August 2013 Accepted: 12 September 2013 Published: 16 September 2013

References

1. Korbling M, Estrov Z: Adult stem cells for tissue repair – a new therapeutic concept? N Engl J Med 2003, 349:570–582.
2. Tagel F, Westenfelder C: Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 2007, 236:3321–3331.
3. Weissman IL: Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000, 100:157–168.
4. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stomaiauolo A, Cossu G, Mavilio F: Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998, 279:1528–1530.
5. Brazelton TR, Rossi FM, Keshet GI, Blau HM: From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000, 290:1775–1779.
6. Orlic D, Kajstura J, Chirimeni S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leni A, Verkman A: Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701–705.
7. Lagasse E, Connors H, Al-Dhalimi M, Reitma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000, 6:1229–1234.
8. Friedenstein AJ: Precursor cells of mechanocytes. Int Rev Cytol 1976, 47:327–359.
9. Fittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshall DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143–147.
10. Keating A: Mesenchymal stromal cells. Curr Opin Hematol 2006, 13:419–425.
11. Lee ST, Maeng H, Chwae YI, Oh DJ, Kim YM, Yang WI: Effect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model. Int J Hematol 2008, 87:227–337.
12. Fei XM, Wu YJ, Chang Z, Xiao KR, Tang YH, Zhou YX, Wang LX, Pan QQ, Wang CY: Co-culture of cord blood CD34(+) cells with human BM mesenchymal stromal cells enhances short-term engraftment of cord blood cells in NOD/SCID mice. Cytotechnology 2007, 57:328–347.
13. Hubbard SR, Till JH: Protein tyrosine kinase structure and function. Annu Rev Biochem 2000, 69:373–398.
14. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548–5557.
15. Terskikh AV, Miyamoto T, Chang C, Diatchenko L, Weissman IL: Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 2003, 102:99–101.
16. Nakajini C, Nagaia N, Ohtsuki S, Yamahara K, Takatake S, Konno T, Hayashi K, Kawashiri MA, Tsubokawa T, Yamagishi M: Gene and protein expression analysis of mesenchymal stem cells derived from rat adipose tissue and bone marrow. Circ J 2011, 75:2260–2268.
17. Qian H, Le Blanc K, Sigvardsson M: Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein. J Biol Chem 2012, 287:25795–25807.
18. Immunological Genome Project. http://www.imgen.org.
19. Son MY, Kim J, Han HW, Woo SM, Cho YS, Kang YK, Han YM: Expression profiles of protein tyrosine kinase genes in human embryonic stem cells. Reproduction 2008, 136:423–432.
20. Spurgeon SL, Jones RC, Ramakrishnan R: High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008, 3:5662.
21. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L, Samaha RR: Large scale real-time PCR validation on gene expression measurements from two commercial long- oligonucleotide microarrays. BMC Genomics 2006, 7:599.
22. Davis TA, Mungunshukal O, Zins S, Day RM, Landauer MR: Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol 2008, 84:713–726.
23. Phinney DG, Kopen G, Isaacson RL, Prockop DJ: Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem 1999, 72:570–585.
24. Peister A, Mellad JA, Lanson BL, Hall BH, Gibson LF, Prockop DJ: Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004, 103:1662–1668.
25. Denker AE, Nicoll SB, Tuan RS: Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int Wound J 2009, 6:11–21.
26. Hoffmann SC, Pearl JP, Blair PJ, Kirk AD: Immune profiling: molecular monitoring in renal transplantation. Front Biosci 2003, 8:e444–e462.
cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000, 9:841–848.

53. Pedemonte E, Benvenuto F, Casaza S, Mancardi G, Oksenberg JR, Uccelli A, Banarizini SE. The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 2007, 8:65.

54. Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002, 85:51–100.

55. Senis YA, Craig AW, Greer PA. Peps/Per and Fer protein-tyrosinekinases play redundant roles in regulating hematopoiesis. Exp Hematol 2003, 31:573–581.

56. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23:7990–8000.

57. Salaszyr RM, Klees RF, Williams WA, Boskey A, Plopper GE: Focal adhesion kinase signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells. Exp Cell Res 2007, 313:22–37.

58. Ahmed L, Calle Y, Sayed MA, Karnal JM, Rengaswamy P, Manser E, Meiners S, Nur EBA: Cdk4/2-dependent nuclear translocation of non-receptor tyrosine kinase, ACK. Biochem Biophys Res Commun 2004, 314:571–579.

59. Akerblom B, Ammeren C, Welsh M: A role of FRK in regulation of embryonal pancreatic beta cell formation. Mol Cell Endocrinol 2007, 270:73–78.

60. Field LA, Deyarmin B, Shriver CD, Ellsworth DL, Ellsworth RE: Laser microdissection for gene expression profiling. Methods Mol Biol 2011, 755:1–45.

Cite this article as: Anam and Davis: Comparative analysis of gene transcripts for cell signaling receptors in bone marrow-derived hematopoietic stem/progenitor cell and mesenchymal stem cell populations. Stem Cell Research & Therapy 2013 4:112.

doi:10.1186/scrt323